Lincoln Pharmaceuticals Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Lincoln Pharmaceuticals Ltd is ₹ 618 as of 17 Feb 16:01 . The P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 7.2 on March 2021 to 13.4 on March 2025 . This represents a CAGR of 13.23% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 449.4 crore on March 2021 to ₹ 1104 crore on March 2025 . This represents a CAGR of 19.71% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 20003 crore on March 2025 to ₹ 20003 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 181.47 crore as compare to the Sep '25 revenue of ₹ 170.6 crore. This represent the growth of 6.37% The revenue of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 294.97 crore as compare to the Sep '25 revenue of ₹ 378.8 crore. This represent the decline of -22.13% The ebitda of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 38.74 crore as compare to the Sep '25 ebitda of ₹ 32.66 crore. This represent the growth of 18.62% The ebitda of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 14.86 crore as compare to the Sep '25 ebitda of ₹ 109.53 crore. This represent the decline of -86.43% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 23.67 crore to ₹ 28.6 crore over 7 quarters. This represents a CAGR of 11.42% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -5.55 crore to ₹ -88.7 crore over 7 quarters. This represents a CAGR of 387.29% The Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 4.83 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of -1.94% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
All the assets and business of the erstwhile partnership were transferred to the Company.
The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

About OneSource Specialty Pharma Ltd

Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

FAQs for the comparison of Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Lincoln Pharmaceuticals Ltd or OneSource Specialty Pharma Ltd?

Market cap of Lincoln Pharmaceuticals Ltd is 1,366 Cr while Market cap of OneSource Specialty Pharma Ltd is 20,042 Cr

What are the key factors driving the stock performance of Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

As of May 5, 2026, the Lincoln Pharmaceuticals Ltd stock price is INR ₹682.1. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1748.25.

How do dividend payouts of Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Lincoln Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.